Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) FCF Margin (2016 - 2026)

Iradimed has reported FCF Margin over the past 14 years, most recently at 35.88% for Q1 2026.

  • Quarterly FCF Margin rose 3283.0% to 35.88% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 36.6% through Mar 2026, up 1718.0% year-over-year, with the annual reading at 28.98% for FY2025, 493.0% up from the prior year.
  • FCF Margin was 35.88% for Q1 2026 at Iradimed, down from 56.13% in the prior quarter.
  • Over five years, FCF Margin peaked at 59.36% in Q2 2023 and troughed at 11.31% in Q1 2023.
  • The 5-year median for FCF Margin is 21.84% (2023), against an average of 22.85%.
  • Year-over-year, FCF Margin tumbled -2389bps in 2022 and then skyrocketed 4796bps in 2023.
  • A 5-year view of FCF Margin shows it stood at 19.01% in 2022, then increased by 15bps to 21.84% in 2023, then decreased by -25bps to 16.49% in 2024, then skyrocketed by 240bps to 56.13% in 2025, then plummeted by -36bps to 35.88% in 2026.
  • Per Business Quant, the three most recent readings for IRMD's FCF Margin are 35.88% (Q1 2026), 56.13% (Q4 2025), and 27.58% (Q3 2025).